- 0112–18m to US LDT EXO-OC.
- 02OC2200 halted by biorepository variability.
- 03Biology supported; OC vs benign signal.
- 04Plan: refine EXO-NET, panel; US lab validation H1-2028.
INOVIQ (ASX: IIQ) has mapped a 12-to-18-month pathway to commercialise its EXO-OC ovarian cancer test as a US laboratory developed test (LDT), after an independent technical review supported its assessment of why the OC2200 verification study could not be completed.
The review confirmed that differences in pre-analytical sample collection and handling across five commercial biorepositories were the largest source of variability, materially affecting biomarker measurements and preventing a reliable assessment of the multi-marker algorithm across the full cohort.
It also found evidence supporting EXO-OC’s underlying biological relevance, with the test distinguishing ovarian cancer from benign gynaecological conditions in samples from a single collection site.
The OC2200 study was discontinued after biorepository sample variability reduced the amount of quantifiable biomarker data available and prevented meaningful evaluation of EXO-OC performance.
INOVIQ is now targeting the first half of 2028 for completion of laboratory validation, ahead of potential LDT commercialisation through a US laboratory partner.
Independent Review Conducted
Independent reviewer Dr Mathew Moore of US-based contract diagnostics organisation ResearchDx recomputed the OC2200 results and concluded that INOVIQ’s technical assessment was accurate, reproducible, and appropriately interpreted.
OC2200 samples contained substantially lower measurable microRNA (miRNA) biomarker levels than the earlier OC500 study, with most miRNA panel measurements either at or above the assay’s reliable measurement range or failing to amplify.
The reviewer recommended optimising tumour-specific extracellular vesicle capture to improve the signal-to-noise ratio, refining the biomarker panel and implementing consistent sample collection protocols before further clinical evaluation.
“Importantly, the review confirmed that these factors are addressable through assay optimisation and standardised sample collection protocols,” chair Peter Gunzburg said.
“The board believes that, notwithstanding the OC2200 results, our science is sound and we now continue to advance the EXO-OC test towards commercialisation in the US with an enhanced understanding of what is required to succeed.”
Staged Commercialisation Pathway
INOVIQ has begun the first stage of its revised program, focused on enhancing EXO-NET technology for tumour-specific capture and refining the EXO-OC biomarker panel to improve assay performance.
Clinical verification will then assess the optimised assay in an independent cohort including average and high-risk women with ovarian cancer using samples collected under a standardised protocol.
Planned to run through the first half of 2028, laboratory validation will involve technology transfer, optimisation, and validation with a US laboratory partner, while INOVIQ evaluates selected biobanks and academic and specialist clinical sites in Australia and the US for consistently collected specimens.
Successful laboratory validation would position EXO-OC for deployment as an LDT, with the laboratory partner expected to lead commercial launch, pricing, and reimbursement activities.
INOVIQ ultimately intends to further develop the test as an in vitro diagnostic for broader ovarian cancer screening.
Get the wire before the market opens.
The ASX small-cap stories that matter, filed before 9am AEST. Curated by the Small Caps desk.